Praxis Precision Medicines, Inc. Announces Proposed Public Offering

Core Viewpoint - Praxis Precision Medicines, Inc. has announced a proposed public offering of its common stock and prefunded warrants to certain investors, with all securities offered by the company [1] Group 1: Offering Details - The offering will include a 30-day option for underwriters to purchase additional shares up to 15% of the total shares sold at the public offering price, minus underwriting discounts and commissions [1] - The offering is being managed by TD Cowen, Piper Sandler, Guggenheim Securities, and Truist Securities as joint book-running managers [2] - The offering is made under a shelf registration statement on Form S-3ASR, which became effective upon filing on December 23, 2024 [3] Group 2: Prospectus Information - The proposed offering will be conducted only through a preliminary prospectus supplement and the accompanying base prospectus [3] - Interested parties can obtain a copy of the preliminary prospectus from the specified financial institutions [3]